Our Answer to AMR

We must take, use and make antibiotics responsibly. Therefore, as part of our responsibility, we are dedicated to making the best and most sustainable antibiotics on this planet.

To prevent that we unnecessarily contribute to antibiotic resistance, we use the best available technology to manufacture all our APIs and drug products. We invest in dedicated state-of-the-art waste water treatment plants, solid waste management and air filters and aim to minimize our impact on the environment and keep our planet clean.

Leading the way in producing antibiotics responsibly

Antimicrobial activity testing

 

To minimize any negative impact our operations may potentially have on the growing threat of AMR, we have implemented methodologies to detect antibiotic activity levels in our wastewater, as part of our Sustainable Antibiotics Program. Our tests are easy to use and have been frequently applied at all our sites since September 2016. Our current detection level is 50 parts per billion (equivalent to 50 mg per 1,000 liters based on Penicillin G).

 

With the Environmental Working Group of the AMR Industry Alliance, we will define science- driven, risk-based targets for discharge concentrations with regard to antibiotics, as well as good-practice methods to reduce the environmental impact of manufacturing discharges.

 

PureActives®

 

Our unique, patented enzymatic technology completely replaces the traditional antibiotic production process and eliminates the use of solvents or other chemicals. The antibiotic active pharmaceutical ingredients and drug products we make using our green technology are marketed under the name PureActives® and fully support our promise: Quality.Reliability.Sustainability.

Our supplier sustainability program

 

To make sure our main suppliers do business in ways that align with our own values and vision regarding sustainability, they need to go through our Supplier Sustainability Program. This means that, before we do business with them, they need to officially agree to abide by the DSP Code of Conduct and undergo an EcoVadis assessment (developed by the Together for Sustainability initiative). Additionally, at the end of 2017, we will carry out our first AMR survey with our API and intermediate suppliers. The aim will be to increase awareness of the environmental angle of AMR, particularly pollution due to irresponsible manufacturing. The survey will focus on the environmental management systems and waste management and discharge control practices applied by our suppliers and manufacturing partners.

 

We recently joined the Pharmaceutical Supply Chain Initiative (PSCI) platform, which aims to create better social, economic, health, safety and environmental outcomes for all those involved in the pharmaceutical supply chain. This includes fair and safe work conditions and practices, responsible business practices and environmental sustainability, and the efficient use of resources.

 

Both our Code of Conduct and assessment s cover matters such as sustainable procurement, environment, labor practices, and fair business practices, as well as other areas covering our three sustainability dimensions of People, Planet, and Profit.

 

Read more about the industry action on AMR here.

Copyright © 2017 DSM Sinochem Pharmaceuticals

Join the conversation

Follow us on Facebook Follow us on Twitter Follow us on LinkedIn
DSM Sinochem Pharmaceuticals logo

We must take, use and make antibiotics responsibly. Therefore, as part of our responsibility, we are dedicated to making the best and most sustainable antibiotics on this planet.

To prevent that we unnecessarily contribute to antibiotic resistance, we use the best available technology to manufacture all our APIs and drug products. We invest in dedicated state-of-the-art waste water treatment plants, solid waste management and air filters and aim to minimize our impact on the environment and keep our planet clean.

Leading the way in producing antibiotics responsibly

Antimicrobial activity testing

 

To minimize any negative impact our operations may potentially have on the growing threat of AMR, we have implemented methodologies to detect antibiotic activity levels in our wastewater, as part of our Sustainable Antibiotics Program. Our tests are easy to use and have been frequently applied at all our sites since September 2016. Our current detection level is 50 parts per billion (equivalent to 50 mg per 1,000 liters based on Penicillin G).

 

With the Environmental Working Group of the AMR Industry Alliance, we will define science- driven, risk-based targets for discharge concentrations with regard to antibiotics, as well as good-practice methods to reduce the environmental impact of manufacturing discharges.

 

Pureactives®

 

Our unique, patented enzymatic technology completely replaces the traditional antibiotic production process and eliminates the use of solvents or other chemicals. The antibiotic active pharmaceutical ingredients and drug products we make using our green technology are marketed under the name PureActives® and fully support our promise: Quality.Reliability.Sustainability.

Our supplier sustainability program

 

To make sure our main suppliers do business in ways that align with our own values and vision regarding sustainability, they need to go through our Supplier Sustainability Program. This means that, before we do business with them, they need to officially agree to abide by the DSP Code of Conduct and undergo an EcoVadis assessment (developed by the Together for Sustainability initiative). Additionally, at the end of 2017, we will carry out our first AMR survey with our API and intermediate suppliers. The aim will be to increase awareness of the environmental angle of AMR, particularly pollution due to irresponsible manufacturing. The survey will focus on the environmental management systems and waste management and discharge control practices applied by our suppliers and manufacturing partners.

 

We recently joined the Pharmaceutical Supply Chain Initiative (PSCI) platform, which aims to create better social, economic, health, safety and environmental outcomes for all those involved in the pharmaceutical supply chain. This includes fair and safe work conditions and practices, responsible business practices and environmental sustainability, and the efficient use of resources.

 

Both our Code of Conduct and assessments cover matters such as sustainable procurement, environment, labor practices, and fair business practices, as well as other areas covering our three sustainability dimensions of People, Planet, and Profit.

 

Read about the industry action on AMR here.